Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1978 1
2000 1
2002 1
2003 1
2004 2
2005 1
2006 1
2007 2
2008 2
2010 1
2012 2
2013 2
2014 1
2015 1
2016 2
2017 2
2018 3
2019 1
2020 1
2021 1
2022 1
2024 4
2025 5

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
The emergence of mesencephalic trigeminal neurons.
Lipovsek M, Ledderose J, Butts T, Lafont T, Kiecker C, Wizenmann A, Graham A. Lipovsek M, et al. Among authors: lafont t. Neural Dev. 2017 Jun 21;12(1):11. doi: 10.1186/s13064-017-0088-z. Neural Dev. 2017. PMID: 28637511 Free PMC article.
Population pharmacokinetics of oxaliplatin.
Delord JP, Umlil A, Guimbaud R, Grégoire N, Lafont T, Canal P, Bugat R, Chatelut E. Delord JP, et al. Among authors: lafont t. Cancer Chemother Pharmacol. 2003 Feb;51(2):127-31. doi: 10.1007/s00280-002-0550-3. Epub 2002 Dec 4. Cancer Chemother Pharmacol. 2003. PMID: 12647013
Pharmacokinetic interaction between pazopanib and cisplatin regimen.
Imbs DC, Diéras V, Bachelot T, Campone M, Isambert N, Joly F, Jimenez M, Lafont T, Chatelut E. Imbs DC, et al. Among authors: lafont t. Cancer Chemother Pharmacol. 2016 Feb;77(2):385-92. doi: 10.1007/s00280-015-2953-y. Epub 2016 Jan 16. Cancer Chemother Pharmacol. 2016. PMID: 26779916 Clinical Trial.
Prophylaxis for renal patients at risk of COVID-19 infection: results from the intranasal niclosamide randomised, double blinded, placebo controlled arm of the PROTECT-V platform trial.
Humphrey TJL, Qian W, Chen-Xu M, Dowling F, Gatley K, Adhikari R, Hensman T, Stockley L, Bassi A, Bathla N, Dasgupta I, Dosanjh DPS, Jellingsø M, Sørensen P, Jensen ML, Callesen AW, Bradley JR, Jha V, Sommer MOA, Hiemstra TF, Smith RM; PROTECT-V consortium. Humphrey TJL, et al. BMC Infect Dis. 2025 Feb 11;25(1):204. doi: 10.1186/s12879-025-10584-4. BMC Infect Dis. 2025. PMID: 39934669 Free PMC article. Clinical Trial.
Pharmacokinetics of heated intraperitoneal oxaliplatin.
Ferron G, Dattez S, Gladieff L, Delord JP, Pierre S, Lafont T, Lochon I, Chatelut E. Ferron G, et al. Among authors: lafont t. Cancer Chemother Pharmacol. 2008 Sep;62(4):679-83. doi: 10.1007/s00280-007-0654-x. Epub 2007 Dec 15. Cancer Chemother Pharmacol. 2008. PMID: 18084764 Clinical Trial.
Cetuximab pharmacokinetic/pharmacodynamics relationships in advanced head and neck carcinoma patients.
Le Louedec F, Alix-Panabières C, Lafont T, Allal BC, Garrel R, Digue L, Guigay J, Cupissol D, Delord JP, Lallemant B, Alfonsi M, Aubry K, Mazel M, Becher F, Perriard F, Chatelut E, Thomas F. Le Louedec F, et al. Among authors: lafont t. Br J Clin Pharmacol. 2019 Jun;85(6):1357-1366. doi: 10.1111/bcp.13907. Epub 2019 Apr 13. Br J Clin Pharmacol. 2019. PMID: 30811063 Free PMC article. Clinical Trial.
Simultaneous monitoring of pazopanib and its metabolites by UPLC-MS/MS.
Paludetto MN, Puisset F, Le Louedec F, Allal B, Lafont T, Chatelut E, Arellano C. Paludetto MN, et al. Among authors: lafont t. J Pharm Biomed Anal. 2018 May 30;154:373-383. doi: 10.1016/j.jpba.2018.03.013. Epub 2018 Mar 9. J Pharm Biomed Anal. 2018. PMID: 29571135
31 results